These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38042525)

  • 1. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    Jänne PA; Planchard D; Kobayashi K; Cheng Y; Lee CK; Valdiviezo N; Laktionov K; Yang TY; Yu Y; Kato T; Jiang L; Chewaskulyong B; Lucien Geater S; Maurel JM; Rojas C; Takahashi T; Havel L; Shepherd FA; Tanaka K; Ghiorghiu D; Amin NP; Armenteros-Monterroso E; Huang X; Chaudhry AA; Yang JC
    J Clin Oncol; 2024 Mar; 42(7):808-820. PubMed ID: 38042525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
    J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
    Saw SPL; Low YF; Lai GGY; Chan LL; Wong WKY; Tsui G; Chen OH; Seet AOL; Tan WC; Tan AC; Chan JWK; Teh YL; Tan WL; Ng QS; Ang MK; Kanesvaran R; Lim DWT; Tan DSW; Mok TSK; Li MSC
    Lung Cancer; 2024 Jul; 193():107856. PubMed ID: 38889498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).
    Lu S; Dong X; Jian H; Chen J; Chen G; Sun Y; Ji Y; Wang Z; Shi J; Lu J; Chen S; Lv D; Zhang G; Liu C; Li J; Yu X; Lin Z; Yu Z; Wang Z; Cui J; Xu X; Fang J; Feng J; Xu Z; Ma R; Hu J; Yang N; Zhou X; Wu X; Hu C; Zhang Z; Lu Y; Hu Y; Jiang L; Wang Q; Guo R; Zhou J; Li B; Hu C; Tong W; Zhang H; Ma L; Chen Y; Jie Z; Yao Y; Zhang L; Weng J; Li W; Xiong J; Ye X; Duan J; Yang H; Sun M; Wei H; Wei J; Zhang Z; Wu Q
    Cancer Commun (Lond); 2024 Sep; 44(9):1005-1017. PubMed ID: 39016053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
    Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.
    Inutsuka Y; Iwama E; Shiraishi Y; Yoneshima Y; Shibahara D; Tanaka K; Okamoto I
    Respir Investig; 2024 May; 62(3):334-338. PubMed ID: 38412569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
    Planchard D; Feng PH; Karaseva N; Kim SW; Kim TM; Lee CK; Poltoratskiy A; Yanagitani N; Marshall R; Huang X; Howarth P; Jänne PA; Kobayashi K
    ESMO Open; 2021 Oct; 6(5):100271. PubMed ID: 34543864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    Park S; Baldry R; Jung HA; Sun JM; Lee SH; Ahn JS; Kim YJ; Lee Y; Kim DW; Kim SW; Lee KH; Lee WJ; Choi JW; Chong K; Lee JI; Gwon SH; Son NH; Ahn MJ
    J Clin Oncol; 2024 Aug; 42(23):2747-2756. PubMed ID: 38828959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis.
    Xing P; Mu Y; Hao X; Wang Y; Li J
    Clin Transl Oncol; 2019 Oct; 21(10):1424-1431. PubMed ID: 30864019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
    Goss G; Tsai CM; Shepherd FA; Ahn MJ; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R; Cantarini M; Johnson M; Mitsudomi T; Jänne PA; Yang JC
    Ann Oncol; 2018 Mar; 29(3):687-693. PubMed ID: 29293889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
    Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib with or without Chemotherapy in
    Planchard D; Jänne PA; Cheng Y; Yang JC; Yanagitani N; Kim SW; Sugawara S; Yu Y; Fan Y; Geater SL; Laktionov K; Lee CK; Valdiviezo N; Ahmed S; Maurel JM; Andrasina I; Goldman J; Ghiorghiu D; Rukazenkov Y; Todd A; Kobayashi K;
    N Engl J Med; 2023 Nov; 389(21):1935-1948. PubMed ID: 37937763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
    Okuma Y; Nomura S; Ninomiya K; Gyotoku H; Murakami S; Kogure Y; Harada D; Okishio K; Okamoto H; Goto Y
    Future Oncol; 2023 Jul; 19(22):1515-1521. PubMed ID: 37577772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.
    Tian W; Niu L; Zhou R; Wang Z; Ning J; Lu R; Shi Y; Tan Z
    Cancer Med; 2024 Aug; 13(16):e70083. PubMed ID: 39206619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS; Wu Y-L; Ahn M-J; Garassino MC; Kim HR; Ramalingam SS; Shepherd FA; He Y; Akamatsu H; Theelen WS; Lee CK; Sebastian M; Templeton A; Mann H; Marotti M; Ghiorghiu S; Papadimitrakopoulou VA;
    N Engl J Med; 2017 Feb; 376(7):629-640. PubMed ID: 27959700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
    Felip E; Cho BC; Gutiérrez V; Alip A; Besse B; Lu S; Spira AI; Girard N; Califano R; Gadgeel SM; Yang JC; Yamamoto S; Azuma K; Kim YJ; Lee KH; Danchaivijitr P; Ferreira CG; Cheng Y; Sendur MAN; Chang GC; Wang CC; Prabhash K; Shinno Y; Stroyakovskiy D; Paz-Ares L; Rodriguez-Cid JR; Martin C; Campelo MRG; Hayashi H; Nguyen D; Tomasini P; Gottfried M; Dooms C; Passaro A; Schuler M; Gelatti ACZ; Owen S; Perdrizet K; Ou SI; Curtin JC; Zhang J; Gormley M; Sun T; Panchal A; Ennis M; Fennema E; Daksh M; Sethi S; Bauml JM; Lee SH
    Ann Oncol; 2024 Sep; 35(9):805-816. PubMed ID: 38942080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib after Chemoradiotherapy in Stage III
    Lu S; Kato T; Dong X; Ahn MJ; Quang LV; Soparattanapaisarn N; Inoue T; Wang CL; Huang M; Yang JC; Cobo M; Özgüroğlu M; Casarini I; Khiem DV; Sriuranpong V; Cronemberger E; Takahashi T; Runglodvatana Y; Chen M; Huang X; Grainger E; Ghiorghiu D; van der Gronde T; Ramalingam SS;
    N Engl J Med; 2024 Aug; 391(7):585-597. PubMed ID: 38828946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
    Yang S; Wu S; Zhao Y; Chen G; Zhu B; Li X; Wang K; Shi J; Cang S; Yao W; Fan Y; Fang J; Zhang L; Zhou J; Wu L; Zheng R; Huang M; Pan Y; Yang Z; Sun M; Yu H; Wang D; Huang J; Wang L; Shu Y; Chen Z; Liu C; Li J; Liu J; Sun S; Guo Y; Meng Z; Liu Z; Han Z; Wu G; Lu H; Ma R; Hu S; Zhao G; Zhang L; Liu Z; Xie C; Zhong D; Zhao H; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Chen Z; Zhuang Z; Guo Z; Greco M; Wang T; Zhou A; Shi Y
    Lung Cancer; 2023 Jun; 180():107194. PubMed ID: 37163774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.